The P2Y Purinoceptor 12 pipeline drugs market research report outlays comprehensive information on the P2Y Purinoceptor 12 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the P2Y Purinoceptor 12 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, and Central Nervous System which include the indications Myocardial Infarction, Acute Coronary Syndrome, Inflammatory Pain, and Neuropathic Pain (Neuralgia). It also reviews key players involved in P2Y Purinoceptor 12 targeted therapeutics development with respective active and dormant or discontinued products.
The P2Y Purinoceptor 12 pipeline targets constitutes close to ten molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 1, 1, 1, 2, 1, 1, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
P2Y Purinoceptor 12 overview
P2Y purinoceptor 12 (P2RY12) belongs to the family of G-protein coupled receptors. P2RY12 is a receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. It is not activated by UDP and UTP. It is required for normal platelet aggregation and blood coagulation.
For a complete picture of P2Y Purinoceptor 12’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
